Parabilis Medicines IPO
Parabilis Medicines is a biotechnology company focused on developing novel therapeutics for serious diseases. The company works on advancing drug candidates through clinical development with the goal of addressing unmet medical needs. Investors monitor biotech IPOs like Parabilis for breakthrough therapies and commercial potential.
Key Facts
| Industry | Biotechnology |
| Founded | Not publicly disclosed |
| Headquarters | Not publicly disclosed |
| Funding | IPO filed targeting $413M-$476M raise (approximately $450M-$475M), with backing from Regeneron |
About Parabilis Medicines
Parabilis Medicines is a biotechnology company working to develop therapeutic solutions for patients with serious medical conditions. Like many biotech companies, Parabilis likely focuses on specific disease areas where there are significant unmet medical needs and opportunities to develop differentiated treatment approaches.
Biotechnology companies typically advance drug candidates through preclinical studies and multiple phases of clinical trials before seeking regulatory approval. This process requires substantial capital investment, which often necessitates raising funds through private financing rounds and eventually public markets.
The path to an IPO for biotechnology companies depends on multiple factors including clinical progress, competitive landscape, intellectual property position, and the strength of the management team. Companies in this sector often go public to fund late-stage clinical development and prepare for potential product commercialization.
IPO Status
Parabilis Medicines, a Cambridge-based biotechnology company, has filed for an IPO seeking to raise between $413 million and $476 million (with most sources citing approximately $450-475 million). The company set terms for its public offering in early June 2026 and has backing from Regeneron. The proceeds are intended to advance the company's lead peptide-based drug candidate into Phase 3 clinical trials for desmoid tumors, as well as to support its broader peptide pipeline. The IPO filing represents a significant milestone for Parabilis as it transitions from a private biotechnology company to public markets. The substantial offering size reflects both the capital-intensive nature of advancing clinical programs through Phase 3 trials and investor interest in the company's peptide-based therapeutic approach. The company appears to be timing its public offering to coincide with advancement of its lead desmoid tumor program, a strategic move common among biotech companies seeking to maximize investor interest.
Competitors
Frequently Asked Questions
Does Parabilis Medicines have a stock?
Parabilis Medicines has not had an IPO yet. The company remains privately held, and while it may be considering going public, no official IPO filing or announcement has been made. Sign up for alerts to stay informed.
When is the Parabilis Medicines IPO date?
No IPO date has been announced for Parabilis Medicines. The company has not filed an S-1 registration statement with the SEC, so the timing of any potential public offering remains uncertain. Sign up for alerts to stay informed.
How can I buy Parabilis Medicines stock?
Parabilis Medicines stock is not currently available for public purchase as the company has not completed an IPO. Once public, shares would be available through standard brokerage platforms. Sign up for alerts to stay informed.
Stay Updated on the Parabilis Medicines IPO
Get real-time alerts when Parabilis Medicines files for an IPO, prices shares, or begins trading.
Get IPO Alerts